Clinical Trial

Crizotinib Continuation Clinical Study

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
Trial Details
NCT Number NCT05160922
Lead Sponsor Pfizer
Conditions NSCLC, ALCL, IMT
Enrollment 27 participants
Start Date 2021-12-27
Primary Completion 2028-03-21 (estimated)
Study Completion 2028-03-21 (estimated)
Updated on ClinicalTrials.gov 2026-03-30